The corporate-backed small molecule therapeutic developer has boosted its initial public offering from $90m to nearly $104m.

US-based integrin drug developer Morphic Holding, which counts pharmaceutical companies AbbVie, Novo, Pfizer, GlaxoSmithKline (GSK) and ShangPharma as investors, closed its initial public offering at approximately $104m yesterday. The company had floated on the Nasdaq Global Market in a $90m IPO last week, pricing 6 million shares at $15.00 each. The shares closed at $18.00…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.